LEADER 05376nam 2201429z- 450 001 9910595072903321 005 20231214133423.0 035 $a(CKB)5680000000080797 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/92141 035 $a(EXLCZ)995680000000080797 100 $a20202209d2022 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aClinical Utility of Applying PGx and Deprescribing-Based Decision Support in Polypharmacy$eFuture Perspectives 210 $aBasel$cMDPI Books$d2022 215 $a1 electronic resource (224 p.) 311 $a3-0365-5162-X 311 $a3-0365-5161-1 330 $aPolypharmacy is a necessary and important aspect of drug treatment; however, it becomes a challenge when the medication risks outweigh the benefits for an individual patient. Drug?drug interactions and the introduction of prescribing cascades are common features of polypharmacy, which can lead to ineffectiveness and increased risk of adverse drug reactions (ADR). Genes encoding CYP450 isozymes and other drug-related biomarkers have attracted considerable attention as targets for pharmacogenetic (PGx) testing due to their impact on drug metabolism and response. This Special Issue is devoted to explore the status and initiatives taken to circumvent ineffectiveness and to improve medication safety for polypharmacy patients. Specific areas include drug?drug interactions and consequences thereof in therapeutic management, including PK- and PD-profiling; the application of PGx-based guidance and/or decision tools for drug?gene and drug?drug gene interactions; medication reviews; development and application of deprescribing tools; and drivers and barriers to overcome for successful implementation in the healthcare system. 517 $aClinical Utility of Applying PGx and Deprescribing-Based Decision Support in Polypharmacy 606 $aMedicine$2bicssc 606 $aPharmaceutical industries$2bicssc 610 $aacute kidney injury 610 $aearly biomarker 610 $aplasma neutrophil gelatinase-associated lipocalin 610 $asoluble urokinase plasminogen activator receptor 610 $amedication optimization 610 $aolder patients 610 $aemergency department 610 $amultimorbidity 610 $apolypharmacy 610 $apotentially inappropriate medication use 610 $aolder adults 610 $aprevalence 610 $adeterminants 610 $achronic 610 $aoutpatient 610 $a2019 Beers criteria 610 $aEthiopia 610 $apharmacogenomics 610 $apersons with diabetes 610 $adrug?drug interactions 610 $adrug?gene interactions 610 $acytochrome P450 610 $aSLCO1B1 610 $adrug interaction checkers 610 $aadverse drug reactions 610 $apharmacogenetics 610 $apersonalized medicine 610 $aphenprocoumon 610 $aDOACs 610 $ableeding 610 $athromboembolism 610 $aHLA 610 $adrug hypersensitivity 610 $aabacavir 610 $aallopurinol 610 $aflucloxacillin 610 $aantiepileptic drugs 610 $acost-effectiveness 610 $ashared medication record 610 $amedication reconciliation 610 $adrug information service 610 $ahospital pharmacy service 610 $aelectronic prescribing 610 $aelectronic medical record 610 $aclinical pharmacist 610 $aCYP2D6 610 $aCYP2D7P 610 $aCYP2D8P 610 $acopy number variation 610 $aCNV 610 $agenotyping 610 $a5?nuclease assay 610 $aHRM 610 $ahigh resolution melting 610 $adrug metabolization 610 $aextracellular vesicles 610 $aexosomes 610 $amicrovesicles 610 $apharmacogene expression 610 $amedication review 610 $adeprescriptions 610 $aquality of life 610 $aaged 610 $aaged, 80 and over 610 $anursing homes 610 $adeprescribing 610 $amedication-based risk score 610 $ahealth outcomes 610 $acytochromes 610 $aCYP1A2 610 $aadverse drug reaction 610 $aantipsychotics 610 $aolanzapine 610 $aclozapine 610 $aloxapine 610 $achildren 610 $ayouth 610 $adigital decision-support 610 $ahealth services research 610 $ageneral practice 610 $aprocess evaluation 610 $aantidepressants 610 $autility 610 $apopulation-based 610 $aappropriateness 610 $amedication adherence 610 $adigital health 615 7$aMedicine 615 7$aPharmaceutical industries 700 $aVermehren$b Charlotte$4edt$01296269 702 $aWestergaard$b Niels$4edt 702 $aVermehren$b Charlotte$4oth 702 $aWestergaard$b Niels$4oth 906 $aBOOK 912 $a9910595072903321 996 $aClinical Utility of Applying PGx and Deprescribing-Based Decision Support in Polypharmacy$93023932 997 $aUNINA